长链非编码 RNA ZNF667-AS1 作为诊断和预测胶质瘤患者的潜在生物标志物分析。
Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients.
机构信息
Department of Oncology and Hematology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, 430015 Hubei, China.
Department of Oncology, First People's Hospital of Zaoyang, Zaoyang, 441200 Hubei, China.
出版信息
Dis Markers. 2020 Nov 16;2020:8895968. doi: 10.1155/2020/8895968. eCollection 2020.
OBJECTIVE
Long noncoding RNAs (lncRNAs) have been strongly associated with various types of cancer. The present study aimed at exploring the diagnostic and prognostic value of lncRNA Zinc finger protein 667-antisense RNA 1 (ZNF667-AS1) in glioma patients. . The expressions of ZNF667-AS1 were detected in 155 glioma tissues and matched normal brain tissue samples by qRT-PCR. The receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of ZNF667-AS1. The association between the ZNF667-AS1 expression and clinicopathological characteristics was analyzed by the chi-square test. The Kaplan-Meier method was performed to determine the influence of the ZNF667-AS1 expression on the overall survival and disease-free survival of glioma patients. The Cox regression analysis was used to evaluate the effect of independent prognostic factors on survival outcome. Cell proliferation was measured by the respective cell counting Kit-8 (CCK-8) assays.
RESULTS
We observed that ZNF667-AS1 was significantly upregulated in glioma tissues compared to normal tissue samples ( < 0.01). Higher levels of ZNF667-AS1 were positively associated with the WHO grade ( = 0.018) and KPS score ( = 0.008). ROC assays revealed that the high ZNF667-AS1 expression had an AUC value of 0.8541 (95% CI: 0.8148 to 0.8934) for glioma. Survival data revealed that glioma patients in the high ZNF667-AS1 expression group had significantly shorter 5-year overall survival ( = 0.0026) and disease-free survival ( = 0.0005) time than those in the low ZNF667-AS1 expression group. Moreover, multivariate analyses confirmed that the ZNF667-AS1 expression was an independent predictor of the overall survival and disease-free survival for glioma patients. Functionally, we found that knockdown of ZNF667-AS1 suppressed the proliferation of glioma cells.
CONCLUSIONS
Our results suggest that ZNF667-AS1 could be used as a potential diagnostic and prognostic biomarker in glioma.
目的
长链非编码 RNA（lncRNA）与多种类型的癌症密切相关。本研究旨在探讨锌指蛋白 667 反义 RNA 1（ZNF667-AS1）在脑胶质瘤患者中的诊断和预后价值。方法：采用 qRT-PCR 检测 155 例脑胶质瘤组织及配对正常脑组织样本中的 ZNF667-AS1 表达水平。采用受试者工作特征（ROC）曲线评估 ZNF667-AS1 的诊断价值。采用卡方检验分析 ZNF667-AS1 表达与临床病理特征的关系。采用 Kaplan-Meier 法确定 ZNF667-AS1 表达对脑胶质瘤患者总生存和无病生存的影响。采用 Cox 回归分析评估独立预后因素对生存结局的影响。采用细胞计数试剂盒（CCK-8）检测细胞增殖。
结果
我们观察到，与正常组织样本相比，脑胶质瘤组织中 ZNF667-AS1 表达显著上调（ < 0.01）。ZNF667-AS1 水平较高与 WHO 分级（ = 0.018）和 KPS 评分（ = 0.008）呈正相关。ROC 分析显示，高 ZNF667-AS1 表达对脑胶质瘤的 AUC 值为 0.8541（95%CI：0.8148 至 0.8934）。生存数据显示，ZNF667-AS1 高表达组脑胶质瘤患者的 5 年总生存率（ = 0.0026）和无病生存率（ = 0.0005）显著短于 ZNF667-AS1 低表达组。此外，多因素分析证实 ZNF667-AS1 表达是脑胶质瘤患者总生存和无病生存的独立预后因素。功能上，我们发现敲低 ZNF667-AS1 抑制了脑胶质瘤细胞的增殖。
结论
我们的研究结果表明，ZNF667-AS1 可作为脑胶质瘤的潜在诊断和预后生物标志物。
Zotero 插件